Initial Warrant Clause Samples

Initial Warrant. In addition to the payments set forth in Section 3.6, Solazyme will grant to ADM a warrant covering 500,000 shares of Stock. Solazyme agrees to prepare a registration statement pursuant to which the warrant and shares of Stock issuable upon exercise of the warrant will be registered under the Securities Act of 1933, and to file such registration statement with the SEC, within thirty (30) days of the Effective Date. Solazyme agrees to use its best efforts to cause such registration statement to be declared effective as soon as practicable following filing. The warrant will be issued promptly following the date the SEC declares the registration statement to be effective. The warrant will vest in equal monthly installments over five (5) years from the Manufacturing Commencement Date.

Initial Warrant. On the Closing Date, the Company shall issue to the Lender a Warrant (the "Initial Warrant") to purchase up to an aggregate of 965,000 Warrant Shares. Immediately after the tenth trading day following the Closing Date, the Company and the Lender shall agree as to the exercise price of such Warrant in accordance with the formula set forth in Section 5.1(b) hereof.

Initial Warrant. On the Closing Date, the Arrangers will be issued warrants to purchase 2% of the Conv Pref of NewCo on a fully-diluted basis as of date of exercise, at an exercise price of $0.01 per share, which will have a 7-year term from the Closing Date and will be exercisable in part or in full at any time during such term. If ECP converts its Conv Pref to common stock, such warrants shall become exercisable into common stock (or dragged into common stock if ECP coverts after the Arrangers have exercised their warrants for Conv Pref). For the avoidance of doubt, only the Arrangers shall be allocated Initial Warrants. If the Arrangers participate in the Incremental Facility, the Arrangers will be issued additional warrants on the foregoing terms to purchase an additional 0.5% of the Conv Pref of NewCo on a fully-diluted basis as of date of exercise, at an exercise price of $0.01 per share, which will have a 7-year term from the Closing Date and will be exercisable in part or in full at any time during such term.

Initial Warrant. Company shall deliver the Initial Warrant, duly executed by Company in definitive form as provided in Section 2(f), and shall register such Initial Warrant in the warrant register of Company in the name of Purchaser or as instructed by Purchaser in writing.

Initial Warrant. The Administrative Agent shall have received an executed counterpart of a Warrant Certificate pursuant to which an Initial Warrant shall have been issued for each Lender.

Initial Warrant. At the Closing, Seller’s Parent shall issue to Buyer’s Parent a five (5)-year warrant (“Initial Warrant”) to purchase, at a price per share equal to the then per share Fair Market Value of Common Stock of Seller’s Parent, a number of shares of Common Stock of Seller’s Parent equal to the quotient obtained by dividing (x) one-tenth percent (.1%) of the estimated Premium Amount by (y) the price per share at which Seller’s Parent most recently issued Common Stock (including securities exercisable for Common Stock) prior to the Closing. The Initial Warrant issued to Buyer’s Parent pursuant to this Section shall be in substantially the form set forth in Exhibit D.

Initial Warrant. At the Closing, Seller's Parent shall issue to --------------- Buyer's Parent a five (5)-year warrant ("Initial Warrant") to purchase, at a --------------- price per share equal to the then per share Fair Market Value of Common Stock of Seller's Parent, a number of shares of Common Stock of Seller's Parent equal to the quotient obtained by dividing (x) one-tenth percent (. 1%) of the estimated Premium Amount by (y) the price per share at which Seller's Parent most recently issued Common Stock (including securities exercisable for Common Stock) prior to the Closing. The Initial Warrant issued to Buyer's Parent pursuant to this Section shall be in substantially the form set forth in Exhibit D. ---------

Initial Warrant. At the closing of the purchase and sale of the Debentures, the Company shall grant, issue, and deliver to Purchaser its Stock Purchase Warrant, dated June 27, 1997, in the form attached hereto as EXHIBIT A-2 (the "Initial Warrant"), entitling Purchaser to purchase 300,000 Shares of the Company's common stock, no par value (the "Common Stock") at an Exercise Price of $6.00 per share, at any time and from time to time during the five year period beginning on June 27, 1997.

Initial Warrant. See Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 19, 2021. October 13, 2021 Re: Securities Purchase Agreement, dated as of October 13, 2021 (the “Purchase Agreement”), between MusclePharm Corporation (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Purchase Agreement. Pursuant to Section 2.2(a) of the Purchase Agreement and in satisfaction of a condition of the Company’s obligations under the Purchase Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until 180 days after the Closing Date (such period, the “Restriction Period”), the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to, any shares of Common Stock of the Company or securities convertible, exchangeable or exercisable into, shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned (the “Securities”), or make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of Common Stock or Common Stock Equivalents or publicly disclose the intention to do any of the foregoing. Beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act. Notwithstanding the foregoing, the Restriction Period shall be 90 days if, between 90 and 180 days after the Closing Date, the VWAP is not less than $2.00 per share of Common Stock. Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives a signed lock-up letter agreement...